Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 9/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.54 |
| ▸ | HDAC10 | Q969S8 | 6/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.54 |
| ▸ | NCOR2 | Q9Y618 | 5/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.54 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.54 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.54 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7216736 | 0.87 | CA1 (0.57) | HDAC3HDAC1HDAC2HDAC10HDAC6 | |
| SCHEMBL7789440 | 0.81 | HDAC1 (0.79) | HDAC3HDAC1HDAC2HDAC10HDAC6 | |
| SCHEMBL3223491 | 0.79 | KDM1A (0.60) | HDAC3HDAC1HDAC2HDAC10HDAC6 | |
| SCHEMBL9443457 | 0.79 | ALDH1A1 (0.51) | SMN1; SMN2GAAALDH1A1MAPTNPC1 | |
| SCHEMBL7557929 | 0.79 | TDP1 (0.49) | HDAC3HDAC1HDAC2HDAC10HDAC6 | |
| SCHEMBL1767107 | 0.79 | TSHR (0.42) | HDAC3HDAC1HDAC2HDAC10HDAC6 | |
| SCHEMBL6548819 | 0.78 | CETP (0.67) | HDAC3HDAC1HDAC2HDAC10HDAC6 | |
| SCHEMBL7465385 | 0.78 | GAA (0.53) | HDAC3HDAC1HDAC2SMN1; SMN2GAA | |
| SCHEMBL24811439 | 0.78 | RAB9A (0.62) | HDAC3HDAC1HDAC2HDAC10HDAC6 | |
| SCHEMBL7220693 | 0.76 | CA1 (0.58) | SMN1; SMN2ALDH1A1KMT2AMAPK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160263142-A1 | USE OF A3 ADENOSINE RECEPTOR AGONIST IN OSTEOARTHRITIS TREATMENT | CAN-FITE BIOPHARMA LTD. (IL) | 2016-09-15 | — | — | US | claimed |
| US-9387220-B2 | Method for inducing hepatocyte proliferation and uses thereof | CAN-FITE BIOPHARMA LTD. (IL) | 2016-07-12 | — | — | US | claimed |
| US-20140364388-A1 | METHOD FOR INDUCING HEPATOCYTE PROLIFERATION AND USES THEREOF | CAN-FITE BIOPHARMA LTD. (IL) | 2014-12-11 | — | — | US | claimed |
| US-8846635-B2 | Method for inducing hepatocyte proliferation and uses thereof | CAN-FITE BIOPHARMA LTD. (IL) | 2014-09-30 | — | — | US | claimed |
| EP-2227234-B1 | METHOD FOR INDUCING HEPATOCYTE PROLIFERATION AND USES THEREOF | CAN FITE BIOPHARMA LTD (IL) | 2014-05-07 | — | — | EP | claimed |
| US-20130109645-A1 | ADENOSINE RECEPTOR AGONISTS FOR THE TREATMENT AND PREVENTION OF VASCULAR OR JOINT CAPSULE CALCIFICATION DISORDERS | The united States of America,as represented by Secretary,Dept.,of Health and Human Services (US) | 2013-05-02 | — | — | US | claimed |
| WO-2011123518-A1 | ADENOSINE RECEPTOR AGONISTS FOR THE TREATMENT AND PREVENTION OF VASCULAR OR JOINT CAPSULE CALCIFICATION DISORDERS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-10-06 | — | — | WO | claimed |
| US-20100249053-A1 | METHOD FOR INDUCING HEPATOCYTE PROLIFERATION AND USES THEREOF | CAN-FITE BIOPHARMA LTD. (IL) | 2010-09-30 | — | — | US | claimed |
| US-7589075-B2 | Use of an adenosine A3 receptor agonist for inhibition of viral replication | CAN-FITE BIOPHARMA LTD. (IL) | 2009-09-15 | — | — | US | claimed |
| US-7465715-B2 | Method for treatment of multiple sclerosis | CAN-FITE BIOPHARMA, LTD. (IL) | 2008-12-16 | — | — | US | claimed |
| US-20040106572-A1 | Use of an adenosine a3 receptor agonist for inhibition of viral replication | CAN-FITE BIOPHARMA LTD. (IL) | 2004-06-03 | — | — | US | claimed |
| CN-1489470-A | Use of adenosine a3 receptor agonists for inhibiting viral replication | ��������-����˹��ҩ����˾ | 2004-04-14 | — | — | CN | claimed |
| EP-1383515-A1 | ACTIVATION OF NATURAL KILLER CELLS BY ADENOSINE A3 RECEPTOR AGONISTS | Can-Fite Biopharma Ltd. (IL) | 2004-01-28 | — | — | EP | claimed |
| EP-1365776-A2 | USE OF AN ADENOSINE A3 RECEPTOR AGONIST FOR INHIBITION OF VIRAL REPLICATION | Can-Fite Biopharma Ltd. (IL) | 2003-12-03 | — | — | EP | claimed |
| JP-2003514771-A | — | — | 2003-04-22 | — | — | JP | claimed |
| EP-1261322-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING AN ADENOSINE RECEPTOR AGONIST OR ANTAGONIST | Can-Fite Biopharma Ltd. (IL) | 2002-12-04 | — | — | EP | claimed |
| WO-2002083152-A1 | ACTIVATION OF NATURAL KILLER CELLS BY ADENOSINE A3 RECEPTOR AGONISTS | CAN-FITE BIOPHARMA LTD. (IL) | 2002-10-24 | — | — | WO | claimed |
| WO-2002055085-A2 | USE OF AN ADENOSINE A3 RECEPTOR AGONIST FOR INHIBITION OF VIRAL REPLICATION | CAN-FITE BIOPHARMA LTD. (IL) | 2002-07-18 | — | — | WO | claimed |
| WO-2001019360-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING AN ADENOSINE RECEPTOR AGONIST OR ANTAGONIST | CAN-FITE BIOPHARMA LTD. (IL) | 2001-03-22 | — | — | WO | claimed |
| US-5688774-A | ANTIINFLAMMATORY AGENTS, HYPOTENSIVE AGENTS AND CARDIOVASCULAR DISORDERS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-11-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106572-A1 | Use of an adenosine a3 receptor agonist for inhibition of viral replication | ADORA3, ADORA2A, ADORA1 | HDAC3 3465/4885HDAC1 4646/4885HDAC2 4777/4885 |
| US-20140364388-A1 | METHOD FOR INDUCING HEPATOCYTE PROLIFERATION AND USES THEREOF | HGF, HCAR3, HNF4A | HDAC3 1525/4885HDAC1 3807/4885HDAC2 3841/4885 |
| US-20160263142-A1 | USE OF A3 ADENOSINE RECEPTOR AGONIST IN OSTEOARTHRITIS TREATMENT | ADORA3, ADORA2A, ADORA1 | HDAC3 2855/4885HDAC1 4729/4885HDAC2 4693/4885 |
| US-20130109645-A1 | ADENOSINE RECEPTOR AGONISTS FOR THE TREATMENT AND PREVENTION OF VASCULAR OR JOINT CAPSULE CALCIFICATION DISORDERS | NT5E, NT5C2, NT5C3B | HDAC3 4102/4885HDAC1 4600/4885HDAC2 4441/4885 |
| US-20100249053-A1 | METHOD FOR INDUCING HEPATOCYTE PROLIFERATION AND USES THEREOF | HGF, HCAR3, HNF4A | HDAC3 1525/4885HDAC1 3807/4885HDAC2 3841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.